Fig. 1
From: SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α
SOD3 upregulation enhances Doxo chemotherapeutic effects. a, b LLC tumor growth kinetics in Vhcl-, Lov-, Doxo+Vhcl-, or Doxo+Lov-treated WT (a) and SOD3−/− mice (b). Arrows indicate treatment schedule (n = 10 mice/group). c Tumors from WT or SOD3−/− mice treated as above were dissected on day 16 and Doxo was quantified in tumor extracts. d Vhcl- and Lov-treated tumors from WT or SOD3−/− mice were dissected on day 18 (<1 cm3), and SOD3 and CD31 were detected in cryosections by immunohistochemistry (IHC); the two-color merge is shown (n = 10 fields/group; 4 mice/group). e 3-NT detection in paraffin sections of LLC tumors as in d (n = 15 fields/group; 4 mice/group). f LLC-GFP cells were implanted in WT or SOD3−/− mice, Lov-treated as in a, and tumors were dissected on day 21. LLC cells, ECs, and leukocytes were isolated by cell sorting and SOD3 mRNA was determined by qPCR. Data shown as mean ± SEM of triplicates (n = 5 mice/group). g Detection of SOD3 expression (red) and CD31 (green) in sections of Ad-C- or Ad-mSOD3-injected LLC tumors (dissected on day 18); nuclei are DAPI-stained (blue). Arrows in the SOD3 panel indicate the position of CD31+ cells. Bottom panel shows SOD3 fluorescence intensity quantified by ImageJ (15 images/group; 4 mice/group). h Growth kinetics of Ad-C- or Ad-mSOD3-injected LLC tumors. Arrows indicate treatment schedule (n = 9 mice/group). i Doxo quantification in extracts of tumors dissected on day 16 from mice treated as in h. *p < 0.05, **p < 0.01, ***p < 0.001 one-way ANOVA with Dunnett’s post-hoc test using Vhcl group as reference (a, b) or two-tailed Student’s t-test (f–i). Bar, 10 μm (d, g) and 50 μm (e)
